SABCS roundup: No­var­tis shows two-year PFS in breast can­cer sub­groups; As­traZeneca re­veals more En­her­tu da­ta

The San An­to­nio Breast Can­cer Sym­po­sium is tak­ing place this week, and so far, some of the Big Phar­mas are turn­ing out new tri­al da­ta about some of the biggest drugs in the space.

First off, No­var­tis an­nounced that its drug, Kisqali, showed about a year of pro­gres­sion-free sur­vival in pa­tients with dif­fer­ent types of first-line metasta­t­ic breast can­cer. The CDK 4/6 drug was first ap­proved by the FDA in 2017, set­ting it up in di­rect com­pe­ti­tion against Pfiz­er’s Ibrance.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER